Goldman Sachs Starts ORIC Pharmaceuticals (ORIC) at Early-Stage Biotech, 'Potential for differentiated approach in prostate cancer'
Tweet Send to a Friend
Goldman Sachs analyst Corinne Johnson initiates coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Early-Stage Biotech rating.The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
